Aptamers are showing promise in the diagnosis and treatment of a variety of eye ailments. Pegaptanib, an aptamer medication that targets vascular endothelial growth factor, has been authorized for the treatment of age-related macular degeneration and diabetic retinopathy. Several different aptamers targeting angiogenesis-related biomarkers have entered clinical trials for various disorders. Aptamer-based sensors have been created to identify biomarkers for the early detection of eye illnesses such as glaucoma. Aptamers that target proteins implicated in different pathways relevant to eye diseases are also being developed. Aptamers that target biomarkers for ocular malignancies have been found. Aptamer development has the potential to increase our understanding of the etiology of eye illnesses and offer novel treatment methods.

To know more: About the original article click here.